Infanrix Hexa, cjepivo protiv difterije, tetanusa, pertusisa (nestanično, komponentno), hepatitisa B (rDNA), poliomijelitisa (inaktiviranog) i hemofilusa tip b (konjugirano), adsorbirano
The medicinal product has been authorised by the European Commission (EC) via centralised procedure in all EU Member States, based on the European Medicines Agency (EMA) experts' opinion.
| Name | Infanrix Hexa, cjepivo protiv difterije, tetanusa, pertusisa (nestanično, komponentno), hepatitisa B (rDNA), poliomijelitisa (inaktiviranog) i hemofilusa tip b (konjugirano), adsorbirano |
|---|---|
| Active Substance | toksoid difterije toksoid tetanusa toksoid pertusisa filamentozni hemaglutinin pertusisa pertaktin pertusisa površinski antigen virusa hepatitisa B poliovirus tip 1, soj Mahoney (inaktiviran) poliovirus tip 2, soj MEF-1 (inaktiviran) poliovirus tip 3, soj Saukett (inaktiviran) polisaharid hemofilusa influence tip b (poliribozilribitolfosfat) |
| Prescription | na recept |
| Type of prescription | ograničeni recept |
| Distribution | u ljekarni |
| ATC Code | J07CA09 |
| Medicinal product marketed in the Croatia | Da |
| Summary of product characteristics (SmPC), labelling and package leaflet (PL) | download |
| Link to the European Medicines Agency's (EMA) product information | download |
| Link to the European Commission's (EC) decisions | download |
Direct Healthcare Professional Communication
| Name | Date | Download |
|---|---|---|
| Pismo zdravstvenim radnicima o istjecanju cjepiva iz štrcaljki nekoliko različitih cjepiva nositelja odobrenja GlaxoSmithKline Biologicals | 04.04.2018 | GlaxoSmithKline d.o.o. |
